166 related articles for article (PubMed ID: 8785955)
1. Developments in pertussis vaccines leading to reduction and replacement of in vivo testing.
Redhead K
Dev Biol Stand; 1996; 86():263-70. PubMed ID: 8785955
[TBL] [Abstract][Full Text] [Related]
2. Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines.
Xing D; Canthaboo C; Douglas-Bardsley A; Yuen CT; Prior S; Liu Y; Corbel M
Dev Biol (Basel); 2002; 111():57-68. PubMed ID: 12678225
[TBL] [Abstract][Full Text] [Related]
3. Pertussis serological potency test as an alternatively to the intracerebral mouse protection test.
van der Ark A; van Straaten-van de Kappelle I; Hendriksen C; van de Donk H
Dev Biol Stand; 1996; 86():271-81. PubMed ID: 8785956
[TBL] [Abstract][Full Text] [Related]
4. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
[TBL] [Abstract][Full Text] [Related]
5. Development of a nitric oxide induction assay as a potential replacement for the intracerebral mouse protection test for potency assay of pertussis whole cell vaccines.
Canthaboo C; Xing D; Corbel M
Dev Biol Stand; 1999; 101():95-103. PubMed ID: 10566781
[TBL] [Abstract][Full Text] [Related]
6. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
[TBL] [Abstract][Full Text] [Related]
7. Is the mouse weight gain test outdated as a model for the assessment of pertussis toxicity?
Straaten-van der Kappelle IV; van der Gun J; van der Ark A; Hendriksen C
Dev Biol Stand; 1996; 86():344. PubMed ID: 8785984
[No Abstract] [Full Text] [Related]
8. Standardization of acellular pertussis vaccines.
Kreeftenberg JG
Biologicals; 1999 Jun; 27(2):115-7. PubMed ID: 10600198
[TBL] [Abstract][Full Text] [Related]
9. The Pertussis Serological Potency Test. Collaborative study to evaluatereplacement of the Mouse Protection Test.
van der Ark A; van Straaten-van de Kappelle I; Olander RM; Enssle K; Jadhav S; van de Donk H; Hendriksen C
Biologicals; 2000 Jun; 28(2):105-18. PubMed ID: 10885617
[TBL] [Abstract][Full Text] [Related]
10. WHO working group on standardisation and control of acellular pertussis vaccines--report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom.
Xing DK; Corbel MJ; Dobbelaer R; Knezevic I
Vaccine; 2007 Apr; 25(15):2749-57. PubMed ID: 17368348
[TBL] [Abstract][Full Text] [Related]
11. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
[TBL] [Abstract][Full Text] [Related]
12. Key points for the development of mouse immunogenicity test as potency assay for acellular pertussis vaccines.
André M; Poirier B; Bornstein N; Marmonier D; El Zaouk A; Fuchs F
Biologicals; 2000 Dec; 28(4):217-25. PubMed ID: 11237357
[TBL] [Abstract][Full Text] [Related]
13. Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine.
van Straaten-van de Kappelle I; van der Gun JW; Marsman FR; Hendriksen CF; van de Donk HJ
Biologicals; 1997 Mar; 25(1):41-57. PubMed ID: 9167008
[TBL] [Abstract][Full Text] [Related]
14. [Laboratory assessment problems of the efficacy of acellular pertussis vaccines].
Gzyl A
Przegl Epidemiol; 2004; 58(2):361-7. PubMed ID: 15517817
[TBL] [Abstract][Full Text] [Related]
15. Three Rs potential in the development and quality control of pharmaceuticals.
Hartung T
ALTEX; 2001; 18 Suppl 1():3-13. PubMed ID: 11854852
[TBL] [Abstract][Full Text] [Related]
16. Approaches to the control of acellular pertussis vaccines.
Corbel MJ; Xing DK; Bolgiano B; Hockley DJ
Biologicals; 1999 Jun; 27(2):133-41. PubMed ID: 10600202
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
[TBL] [Abstract][Full Text] [Related]
18. Calibration of pertussis toxin BRP batch 1 in a standardised CHO cell-based clustering assay.
Markey K; Douglas-Bardsley A; Hockley J; Le Tallec D; Costanzo A
Pharmeur Bio Sci Notes; 2018; 2018():112-123. PubMed ID: 30272557
[TBL] [Abstract][Full Text] [Related]
19. Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines.
Canthaboo C; Xing D; Douglas A; Corbel M
Biologicals; 2000 Dec; 28(4):241-6. PubMed ID: 11237360
[TBL] [Abstract][Full Text] [Related]
20. A respiratory challenge model for infection with Bordetella pertussis: application in the assessment of pertussis vaccine potency and in defining the mechanism of protective immunity.
Mills KH; Brady M; Ryan E; Mahon BP
Dev Biol Stand; 1998; 95():31-41. PubMed ID: 9855412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
